A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS
VE-CIP1002/2021
Phase 1 other active
Quick answer
A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS for chronic intestinal pseudo-obstruction (CIPO) is a Phase 1 program (other) at Alfasigma S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alfasigma S.p.A.
- Indication
- chronic intestinal pseudo-obstruction (CIPO)
- Phase
- Phase 1
- Modality
- other
- Status
- active